Overexpression of RANKL in osteoblasts: a possible mechanism of susceptibility to bone disease in cystic fibrosis

Journal of Pathology

Volumn 240, Issue 1, 2016, Pages 50-60

  Delion, Martial ^a   Braux, Julien ^a   Jourdain, Marie Laure ^a   Guillaume, Christine ^a   Bour, Camille ^a   Gangloff, Sophie ^a   Pimpec Barthes, Françoise Le ^b   Sermet Gaudelus, Isabelle ^c   Jacquot, Jacky ^a   Velard, Frédéric ^a  

^a UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c INSERM   (France)

Author keywords

bone disease; CFTR correctors; cystic fibrosis; F508del CFTR; OPG; osteoblasts; RANKL

Indexed keywords

CHLORIDE CHANNEL; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; INTERLEUKIN 17; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ARTICLE; BONE DISEASE; BONE MINERALIZATION; CELL MEMBRANE; CELL ULTRASTRUCTURE; CHLORIDE CONDUCTANCE; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; CYSTIC FIBROSIS RELATED BONE DISEASE; DISEASE PREDISPOSITION; EXTRACELLULAR MATRIX; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; OSTEOBLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS;

EID: 84983268451     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4753     Document Type: Article

References (68)

1. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA [erratum in Science 1989 Sep 29;245(4925):1437]. Science 1989; 245: 1066–1073.
2. Stoltz DA, Meyerholz DK, Welsh MJ. Origins of cystic fibrosis lung disease. N Engl J Med 2015; 372: 351–362.
3. Boyle MP, De Boeck K. A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect. Lancet Respir Med 2013; 1: 158–163.
4. Riordan JR. CFTR function and prospects for therapy. Annu Rev Biochem 2008; 77: 701–726.
5. Jacquot J, Delion M, Gangloff S, et al. Bone disease in cystic fibrosis: new pathogenic insights opening novel therapies. Osteoporos Int 2016; 27: 1401–1412.
6. Plant BJ, Goss CH, Plant WD, et al. Management of comorbidities in older patients with cystic fibrosis. Lancet Respir Med 2013; 1: 164–174.
7. Putman MS, Milliren CE, Derrico N, et al. Compromised bone microarchitecture and estimated bone strength in young adults with cystic fibrosis. J Clin Endocrinol Metab 2014; 99: 3399–3407.
8. Aris RM, Merkel PA, Bachrach LK, et al. Guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab 2005; 90: 1888–1896.
9. Buntain HM, Greer RM, Schluter PJ, et al. Bone mineral density in Australian children, adolescents and adults with cystic fibrosis: a controlled cross sectional study. Thorax 2004; 59: 149–155.
10. Paccou J, Zeboulon N, Combescure C, et al. The prevalence of osteoporosis, osteopenia, and fractures among adults with cystic fibrosis: a systematic literature review with meta-analysis. Calcif Tissue Int 2010; 86: 1–7.
11. Sermet-Gaudelus I, Castanet M, Retsch-Bogart G, et al. Update on cystic fibrosis-related bone disease: a special focus on children. Paediatr Respir Rev 2009; 10: 134–142.
12. Aris RM, Renner JB, Winders AD, et al. Increased rate of fractures and severe kyphosis: sequelae of living into adulthood with cystic fibrosis. Ann Intern Med 1998; 128: 186–193.
13. Velard F, Delion M, Le Henaff C, et al. Cystic fibrosis and bone disease: defective osteoblast maturation with the F508del mutation in cystic fibrosis transmembrane conductance regulator. Am J Respir Crit Care Med 2014; 189: 746–748.
14. Gore AP, Kwon SH, Stenbit AE. A roadmap to the brittle bones of cystic fibrosis. J Osteoporos 2010; 2011: 926045.
15. Boyle MP. Update on maintaining bone health in cystic fibrosis. Curr Opin Pulm Med 2006; 12: 453–458.
16. Haworth CS. Impact of cystic fibrosis on bone health. Curr Opin Pulm Med 2010; 16: 616–622.
17. Javier RM, Jacquot J. Bone disease in cystic fibrosis: what's new? Joint Bone Spine 2011; 78: 445–450.
18. Stalvey MS, Clines GA. Cystic fibrosis-related bone disease: insights into a growing problem. Curr Opin Endocrinol Diabetes Obes 2013; 20: 547–552.
19. Putman MS, Greenblatt LB, Sicilian L, et al. Young adults with cystic fibrosis have altered trabecular microstructure by ITS-based morphological analysis. Osteoporos Int 2016; DOI: 10.1007/s00198-016-3557-z.
20. Sermet-Gaudelus I, Souberbielle JC, Ruiz JC, et al. Low bone mineral density in young children with cystic fibrosis. Am J Respir Crit Care Med 2007; 175: 951–957.
21. Le Heron L, Guillaume C, Velard F, et al. Cystic fibrosis transmembrane conductance regulator (CFTR) regulates the production of osteoprotegerin (OPG) and prostaglandin (PG) E(2) in human bone. J Cyst Fibros 2010; 9: 69–72.
22. Shead EF, Haworth CS, Condliffe AM, et al. Cystic fibrosis transmembrane conductance regulator (CFTR) is expressed in human bone. Thorax 2007; 62: 650–651.
23. Le Henaff C, Gimenez A, Hay E, et al. The F508del mutation in cystic fibrosis transmembrane conductance regulator gene impacts bone formation. Am J Pathol 2012; 180: 2068–2075.
24. Le Henaff C, Hay E, Velard F, et al. Enhanced F508del-CFTR channel activity ameliorates bone pathology in murine cystic fibrosis. Am J Pathol 2014; 184: 1132–1141.
25. Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nature Med 2013; 19: 179–192.
26. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001; 142: 5050–5055.
27. Teitelbaum SL. Osteoclasts: what do they do and how do they do it? Am J Pathol 2007; 170: 427–435.
28. Wei S, Siegal GP. Mechanisms modulating inflammatory osteolysis: a review with insights into therapeutic targets. Pathol Res Pract 2008; 204: 695–706.
29. Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys 2008; 473: 139–146.
30. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165–176.
31. Shead EF, Haworth CS, Barker H, et al. Osteoclast function, bone turnover and inflammatory cytokines during infective exacerbations of cystic fibrosis. J Cyst Fibros 2010; 9: 93–98.
32. Ambroszkiewicz J, Sands D, Gajewska J, et al. Bone turnover markers, osteoprotegerin and RANKL cytokines in children with cystic fibrosis. Adv Med Sci 2013; 58: 338–343.
33. Blackwell KA, Raisz LG, Pilbeam CC. Prostaglandins in bone: bad cop, good cop? Trends Endocrinol Metab 2010; 21: 294–301.
34. −/− mice via activation of prostaglandin E2 receptor subtype 4. Am J Pathol 2009; 175: 772–785.
35. 2 inhibits osteolytic breast cancer bone metastasis and estrogen deficiency-induced bone loss. PLoS One 2015; 10: e0122764.
36. Napimoga MH, Demasi AP, Bossonaro JP, et al. Low doses of 15d-PGJ2 induce osteoblast activity in a PPAR-gamma independent manner. Int Immunopharmacol 2013; 16: 131–138.
37. Zhang X, Schwarz EM, Young DA, et al. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest 2002; 109: 1405–1415.
38. Tyagi AM, Srivastava K, Mansoori MN, et al. Estrogen deficiency induces the differentiation of IL-17 secreting Th17 cells: a new candidate in the pathogenesis of osteoporosis. PLoS One 2012; 7: e44552.
39. Liu XH, Kirschenbaum A, Yao S, et al. Interactive effect of interleukin-6 and prostaglandin E2 on osteoclastogenesis via the OPG/RANKL/RANK system. Ann N Y Acad Sci 2006; 1068: 225–233.
40. Stalvey MS, Clines KL, Havasi V, et al. Osteoblast CFTR inactivation reduces differentiation and osteoprotegerin expression in a mouse model of cystic fibrosis-related bone disease. PLoS One 2013; 8: e80098.
41. Tiringer K, Treis A, Fucik P, et al. A Th17- and Th2-skewed cytokine profile in cystic fibrosis lungs represents a potential risk factor for Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 2013; 187: 621–629.
42. Kotake S, Udagawa N, Takahashi N, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999; 103: 1345–1352.
43. Mori G, D'Amelio P, Faccio R, et al. Bone-immune cell crosstalk: bone diseases. J Immunol Res 2015; 2015: 108451.
44. Verkman AS, Jayaraman S. Fluorescent indicator methods to assay functional CFTR expression in cells. Methods Mol Med 2002; 70: 187–196.
45. Van Goor F, Hadida S, Grootenhuis PD, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A 2009; 106: 18825–18830.
46. Wainwright CE, Elborn JS, Ramsey BW, et al. Lumacaftor–ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 2015; 373: 220–231.
47. Eckford PD, Ramjeesingh M, Molinski S, et al. VX-809 and related corrector compounds exhibit secondary activity stabilizing active F508del-CFTR after its partial rescue to the cell surface. Chem Biol 2014; 21: 666–678.
48. Bitam S, Pranke I, Hollenhorst M, et al. An unexpected effect of TNF-alpha on F508del-CFTR maturation and function. F1000Res 2015; 4: 218.
49. Baudouin-Legros M, Colas J, Moriceau S, et al. Long-term CFTR inhibition modulates 15d-prostaglandin J2 in human pulmonary cells. Int J Biochem Cell Biol 2012; 44: 1009–1018.
50. Velard F, Delion M, Lemaire F, et al. Cystic fibrosis bone disease: is the CFTR corrector C18 an option for therapy? Eur Respir J 2015; 45: 845–848.
51. Dif F, Marty C, Baudoin C, et al. Severe osteopenia in CFTR-null mice. Bone 2004; 35: 595–603.
52. Haston CK, Li W, Li A, et al. Persistent osteopenia in adult cystic fibrosis transmembrane conductance regulator-deficient mice. Am J Respir Crit Care Med 2008; 177: 309–315.
53. Pashuck TD, Franz SE, Altman MK, et al. Murine model for cystic fibrosis bone disease demonstrates osteopenia and sex-related differences in bone formation. Pediatr Res 2009; 65: 311–316.
54. Sermet-Gaudelus I, Bianchi ML, Garabedian M, et al. European cystic fibrosis bone mineralisation guidelines. J Cyst Fibros 2011; 10 (Suppl 2): S16-S23.
55. Ousingsawat J, Wanitchakool P, Schreiber R, et al. Anoctamin-6 controls bone mineralization by activating the calcium transporter NCX1. J Biol Chem 2015; 290: 6270–6280.
56. Shead EF, Haworth CS, Gunn E, et al. Osteoclastogenesis during infective exacerbations in patients with cystic fibrosis. Am J Respir Crit Care Med 2006; 174: 306–311.
57. Haworth CS, Selby PL, Webb AK, et al. Inflammatory related changes in bone mineral content in adults with cystic fibrosis. Thorax 2004; 59: 613–617.
58. Shmarina G, Pukhalsky A, Petrova N, et al. TNF gene polymorphisms in cystic fibrosis patients: contribution to the disease progression. J Transl Med 2013; 11: 19.
59. Krum SA, Chang J, Miranda-Carboni G, et al. Novel functions for NFkB: inhibition of bone formation. Nature Rev Rheumatol 2011; 6: 607–611.
60. Chang J, Wang Z, Tang E, et al. Inhibition of osteoblastic bone formation by nuclear factor-kB. Nature Med 2009; 15: 682–689.
61. DiMango E, Ratner AJ, Bryan R, et al. Activation of NF-kB by adherent Pseudomonas aeruginosa in normal and cystic fibrosis respiratory epithelial cells. J Clin Invest 1998; 101: 2598–2605.
62. Tabary O, Escotte S, Couetil JP, et al. Genistein inhibits constitutive and inducible NFkB activation and decreases IL-8 production by human cystic fibrosis bronchial gland cells. Am J Pathol 1999; 155: 473–481.
63. Vij N, Mazur S, Zeitlin PL. CFTR is a negative regulator of NFkB mediated innate immune response. PLoS One 2009; 4: e4664.
64. 2 inhibits multiple steps in the NF-kB signaling pathway. Proc Natl Acad Sci U S A 2000; 97: 4844–4849.
65. Conwell LS, Chang AB. Bisphosphonates for osteoporosis in people with cystic fibrosis. Cochrane Database Syst Rev 2014; 3: CD002010.
66. Lacey DL, Boyle WJ, Simonet WS, et al. Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab. Nature Rev Drug Discov 2012; 11: 401–419.
67. Cohen SB, Dore RK, Lane NE, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008; 58: 1299–1309.
68. Birault V, Solari R, Hanrahan J, et al. Correctors of the basic trafficking defect of the mutant F508del-CFTR that causes cystic fibrosis. Curr Opin Chem Biol 2013; 17: 353–360.